Keyword: Sangamo BioSciences

DNA

13. SB-913

Sangamo Biosciences has been working on its zinc finger nuclease gene-editing platform for many years, long before the emergence of rival method CRISPR, but early readouts from trials haven’t been encouraging.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.